Die Rakete hat gezuendet:HIV - 500 Beiträge pro Seite
eröffnet am 11.02.00 16:23:10 von
neuester Beitrag 19.07.01 19:30:03 von
neuester Beitrag 19.07.01 19:30:03 von
Beiträge: 17
ID: 62.853
ID: 62.853
Aufrufe heute: 0
Gesamt: 3.421
Gesamt: 3.421
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 21:55 | 1030 | |
| vor 1 Stunde | 593 | |
| 20.04.24, 12:11 | 487 | |
| vor 1 Stunde | 475 | |
| gestern 23:31 | 458 | |
| gestern 21:35 | 451 | |
| heute 05:12 | 411 | |
| 15.05.11, 11:34 | 369 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.033,14 | +0,58 | 243 | |||
| 2. | 2. | 1,2000 | -13,04 | 98 | |||
| 3. | 3. | 0,1905 | +0,79 | 89 | |||
| 4. | 4. | 161,64 | +1,87 | 80 | |||
| 5. | 5. | 9,3750 | +1,41 | 75 | |||
| 6. | 6. | 6,9480 | -0,71 | 47 | |||
| 7. | 8. | 0,0160 | -24,17 | 38 | |||
| 8. | 7. | 22,210 | +0,73 | 37 |
Feedback
Die Kursentwicklung in USA geht seit 2 Wochen nur noch
Richtung Norden. (Nadaq Kuerzel:HIV)CEl-SCI Corp
Richtung Norden. (Nadaq Kuerzel:HIV)CEl-SCI Corp
Diese Aktie scheint im Bereich der Krebs- und HIV-Bekaempfung ein
enormes enzial zu haben.
January 25, 2000 09:01 AM
VIENNA, Va., Jan. 25 /PRNewswire/ -- CEL-SCI Corporation (Amex: HIV) (Berlin: LSR) announced today that it hired The Pinnacle Group of New York City as its investor relations counsel.
Commenting on the announcement, Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We have retained The Pinnacle Group due to their excellent track record of enhancing shareholder value for emerging growth companies in all industries. Since we expect to announce the results of various clinical studies with cancer patients soon, we feel that now is the opportune time to increase our visibility with the Wall Street investment community."
CEL-SCI is a leading-edge developer of novel immune therapy products for cancer and infectious diseases. The Company`s most advanced product, Multikine(TM), is being developed to treat head and neck cancer, prostate cancer and breast cancer. Multikine is currently in several Phase II human studies in the U.S. and 5 other countries. The Company, either itself or with a partner, is planning to take the product into Phase III clinical trials for ential approval for sale. CEL-SCI is also using its expertise in immune therapy to develop a ential breakthrough AIDS vaccine, called HGP-30W, which is currently in Phase II human trials. In addition, the Company`s platform technology (L.E.A.P.S. (TM)) is being deployed in 7 R&D collaborations against cancer, infectious diseases and heart disease.
The Pinnacle Group, based in New York City, is a full service investor and public relations agency. The Pinnacle Group currently represents over 20 emerging growth companies including such successful stocks as max internet Commications, Inc., Hollywood.com, Nam Corporation and OSI Pharmaceuticals, Inc.
"CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, ext. 445563, or at http://www.cel-sci.com on the Internet."
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results strated in preclinical studies, timely development of any ential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s ential products and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1999. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
enormes enzial zu haben.
January 25, 2000 09:01 AM
VIENNA, Va., Jan. 25 /PRNewswire/ -- CEL-SCI Corporation (Amex: HIV) (Berlin: LSR) announced today that it hired The Pinnacle Group of New York City as its investor relations counsel.
Commenting on the announcement, Geert Kersten, Chief Executive Officer of CEL-SCI Corporation said, "We have retained The Pinnacle Group due to their excellent track record of enhancing shareholder value for emerging growth companies in all industries. Since we expect to announce the results of various clinical studies with cancer patients soon, we feel that now is the opportune time to increase our visibility with the Wall Street investment community."
CEL-SCI is a leading-edge developer of novel immune therapy products for cancer and infectious diseases. The Company`s most advanced product, Multikine(TM), is being developed to treat head and neck cancer, prostate cancer and breast cancer. Multikine is currently in several Phase II human studies in the U.S. and 5 other countries. The Company, either itself or with a partner, is planning to take the product into Phase III clinical trials for ential approval for sale. CEL-SCI is also using its expertise in immune therapy to develop a ential breakthrough AIDS vaccine, called HGP-30W, which is currently in Phase II human trials. In addition, the Company`s platform technology (L.E.A.P.S. (TM)) is being deployed in 7 R&D collaborations against cancer, infectious diseases and heart disease.
The Pinnacle Group, based in New York City, is a full service investor and public relations agency. The Pinnacle Group currently represents over 20 emerging growth companies including such successful stocks as max internet Commications, Inc., Hollywood.com, Nam Corporation and OSI Pharmaceuticals, Inc.
"CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, ext. 445563, or at http://www.cel-sci.com on the Internet."
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results strated in preclinical studies, timely development of any ential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s ential products and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1999. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
Gestern plus 70%
Zur Info: das neue Kürzel an der nasdaq ist seit 7.Feb. CVM
Thanks, Gomydear
Trading Spotlight
CEL-SCI Corporation Reports Promising Results of Phase II Cancer Study; Multikine(TM) Immunotherapy Study Presented at BIO CEO & Investor Conference
February 15, 2000 10:30 AM
VIENNA, Va., Feb. 15 /PRNewswire/ -- Patients with advanced head and neck cancer receiving CEL-SCI`s immunotherapeutic product, Multikine, prior to surgery or radiation showed promising tumor reductions, according to the results from a clinical trial presented today by Geert Kersten, CEO of CEL-SCI Corporation (Amex: CVM) (Berlin Stock Exchange: LSR), at the BIO CEO & Investor Conference in New York City. The 30-patient Phase II dose escalating trial revealed that 65% (13 of 20) of the patients treated with the lower two doses of Multikine over 18 days showed tumor reductions. Of those, 39% (5 of 13) showed a greater than 50% tumor mass reduction. Multikine was well-tolerated and the treatment showed minimal toxicity.
Multikine is a mixture of immune system regulators known as cytokines. One of those is Interleukin-2, which is presently being used to treat cancer. The goal of this trial was to induce and expand targeted anti-tumor immunity at the tumor site to reduce tumor mass prior to surgery or radiation. Tumor mass reduction, which can be viewed as entially improving patient outcome, is thought to be an indicator that local anti-tumor immunity may have been achieved.
More specifically: -- At the middle dose level, 70% (7 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Three of those seven patients had tumor reductions in excess of 50% in this short period of treatment. The three patients who did not show tumor reductions remained stable.
-- At the lowest dose level, 60% (6 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Two of those six had over 50% tumor reduction during treatment. Three patients remained stable and one showed disease progression.
-- At the highest dose level, 30% (3 of 10) of the patients had tumor reductions while the rest remained stable.
In this study, which was conducted at medical centers in Poland and the Czech Republic, Multikine was given to recently diagnosed head and neck cancer patients with advanced disease. Each patient volunteer was given 6 injections of Multikine over 18 days.
The success of this regimen will ultimately be measured by its effects on the overall recurrence rate in these patients and on quality of life. Currently, about half of advanced head and neck cancer patients have a recurrence of the cancer and the prognosis for these patients is very poor. Many scientists believe that inducing an immune response directed against tumor cells prior to surgical treatment of the tumor will increase the chance of the surgeon achieving higher cure rates or increasing disease-free time. Thus, even a small tumor response to Multikine treatment achieved during this brief treatment before surgery may be sufficient to achieve this goal. A pivotal trial will need to be conducted to strate higher cure rates or increased disease-free time in a larger number of patients.
Head and neck cancer is the sixth most frequent cancer worldwide, with an incidence of 500,000 cases annually. Recent statistics show no reduction in head and neck cancer mortality, but rather a dramatic increase of the disease in certain segments of the population. It occurs mostly in men in their 50s or early 60s. Conventional treatments consist of either surgery, which can be extremely disfiguring, or radiation therapy and chemotherapy, both of which have severe side effects.
The ential market for a more effective first-line or adjunctive treatment for head and neck cancer is about $1 billion.
In keeping with the appropriate scientific rigor, the Company plans to present more detailed results at an appropriate scientific meeting and to publish them in an appropriate scientific journal.
CEL-SCI Corporation is a biopharmaceutical company whose mission is to harness the immune system to combat disease.
CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at http://www.cel-sci.com on the Internet.
February 15, 2000 10:30 AM
VIENNA, Va., Feb. 15 /PRNewswire/ -- Patients with advanced head and neck cancer receiving CEL-SCI`s immunotherapeutic product, Multikine, prior to surgery or radiation showed promising tumor reductions, according to the results from a clinical trial presented today by Geert Kersten, CEO of CEL-SCI Corporation (Amex: CVM) (Berlin Stock Exchange: LSR), at the BIO CEO & Investor Conference in New York City. The 30-patient Phase II dose escalating trial revealed that 65% (13 of 20) of the patients treated with the lower two doses of Multikine over 18 days showed tumor reductions. Of those, 39% (5 of 13) showed a greater than 50% tumor mass reduction. Multikine was well-tolerated and the treatment showed minimal toxicity.
Multikine is a mixture of immune system regulators known as cytokines. One of those is Interleukin-2, which is presently being used to treat cancer. The goal of this trial was to induce and expand targeted anti-tumor immunity at the tumor site to reduce tumor mass prior to surgery or radiation. Tumor mass reduction, which can be viewed as entially improving patient outcome, is thought to be an indicator that local anti-tumor immunity may have been achieved.
More specifically: -- At the middle dose level, 70% (7 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Three of those seven patients had tumor reductions in excess of 50% in this short period of treatment. The three patients who did not show tumor reductions remained stable.
-- At the lowest dose level, 60% (6 of 10) of the patients had tumor reductions after the 18-day treatment with Multikine prior to surgery or radiation. Two of those six had over 50% tumor reduction during treatment. Three patients remained stable and one showed disease progression.
-- At the highest dose level, 30% (3 of 10) of the patients had tumor reductions while the rest remained stable.
In this study, which was conducted at medical centers in Poland and the Czech Republic, Multikine was given to recently diagnosed head and neck cancer patients with advanced disease. Each patient volunteer was given 6 injections of Multikine over 18 days.
The success of this regimen will ultimately be measured by its effects on the overall recurrence rate in these patients and on quality of life. Currently, about half of advanced head and neck cancer patients have a recurrence of the cancer and the prognosis for these patients is very poor. Many scientists believe that inducing an immune response directed against tumor cells prior to surgical treatment of the tumor will increase the chance of the surgeon achieving higher cure rates or increasing disease-free time. Thus, even a small tumor response to Multikine treatment achieved during this brief treatment before surgery may be sufficient to achieve this goal. A pivotal trial will need to be conducted to strate higher cure rates or increased disease-free time in a larger number of patients.
Head and neck cancer is the sixth most frequent cancer worldwide, with an incidence of 500,000 cases annually. Recent statistics show no reduction in head and neck cancer mortality, but rather a dramatic increase of the disease in certain segments of the population. It occurs mostly in men in their 50s or early 60s. Conventional treatments consist of either surgery, which can be extremely disfiguring, or radiation therapy and chemotherapy, both of which have severe side effects.
The ential market for a more effective first-line or adjunctive treatment for head and neck cancer is about $1 billion.
In keeping with the appropriate scientific rigor, the Company plans to present more detailed results at an appropriate scientific meeting and to publish them in an appropriate scientific journal.
CEL-SCI Corporation is a biopharmaceutical company whose mission is to harness the immune system to combat disease.
CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at http://www.cel-sci.com on the Internet.
Die momentanen Kurse laden wieder zum Nachkaufen ein. Der Schlusskurs USA ist fast einen Dollar (0,8 USD) ueber Berlin.
So, ich habe heute noch mal nachgelegt. Hast Du auch welche gekauft,Gomydear?
Hier ein Top-Link mit vielen Infos- Knowledge Base von Cel-CSI:
http://www.geocities.com/WallStreet/1456/celgroup.htm
Kommentar bei Raging Bulls: Thorough research + careful evaluation = successful investment
http://www.geocities.com/WallStreet/1456/celgroup.htm
Kommentar bei Raging Bulls: Thorough research + careful evaluation = successful investment
Hallo Turbocash,
scheint so als ob wir beide alleine die Aktie entdeckt haben. Ja, ich habe mir jetzt 200 Stück zugelegt. Ich habe sie bei Onvista entdeckt, als sie mal zu den Top Performern der Woche gehörte. Vielen Dank für Deine letzte Info (Link). Hört sich doch gut an, oder?
Ich wünsche uns viel Erfolg damit.
Habe übrigens auch in Ariad Pharma etwas investiert, scheint mir auch ganz vernünftig.
scheint so als ob wir beide alleine die Aktie entdeckt haben. Ja, ich habe mir jetzt 200 Stück zugelegt. Ich habe sie bei Onvista entdeckt, als sie mal zu den Top Performern der Woche gehörte. Vielen Dank für Deine letzte Info (Link). Hört sich doch gut an, oder?
Ich wünsche uns viel Erfolg damit.
Habe übrigens auch in Ariad Pharma etwas investiert, scheint mir auch ganz vernünftig.
Gomydear,
ich schau mir Ariad Pharma mal an. TX
ich schau mir Ariad Pharma mal an. TX
Hallo Gomydear,
die letzten zwei Tage liefen ja nicht schlecht fuer uns. Ich hatte Ariad Pharma per Limit geordert, aber leider nicht bekommen, da sie gestern mit 40% abgerauscht sind.Cel-CSI knapp 30%.Hast du noch einen interessanten Biotechwert unter Beobachtung?
die letzten zwei Tage liefen ja nicht schlecht fuer uns. Ich hatte Ariad Pharma per Limit geordert, aber leider nicht bekommen, da sie gestern mit 40% abgerauscht sind.Cel-CSI knapp 30%.Hast du noch einen interessanten Biotechwert unter Beobachtung?
Hallo turbocash,
nein, keine weiteren Biotechs im Visier. Aber interessanten Link gefunden:
www.smallcapsonline.com
Hier werden interessante Aktien vorgestellt, leider fehlt mit im Moment die Zeit tiefer zu recherchieren.
mfg
nein, keine weiteren Biotechs im Visier. Aber interessanten Link gefunden:
www.smallcapsonline.com
Hier werden interessante Aktien vorgestellt, leider fehlt mit im Moment die Zeit tiefer zu recherchieren.
mfg
Neues von cel-sci !
Die Firma gibt bekannT:CEL-SCI COMPLETES EQUITY FINANCING
VIENNA, VA, March 16, 2000 -- CEL-SCI CORPORATION (AMEX: HIV, Berlin Stock
Exchange: LSR) announced today the successful completion of a sale of $7
million of the Company`s common stock to two institutional investors. The
transaction is still subject to the approval of the American Stock Exchange.
Reedland Capital Partners, a division of Financial West Group, facilitated
the transaction.
"We are very pleased by the continued confidence and support from these two
institutional investors who have previously invested in CEL-SCI," indicated
Chief Executive Officer, Geert Kersten. "Pursuant to this sale, the
Company`s cash position exceeds $15 million which we estimate is sufficient
for an additional 2 years worth of operation for the Company. We continue
to be very excited by the results we are seeing with our immunotherapy
product Multikine* which we are preparing to take into a potential phase III
clinical trial for head and neck cancer next year. In addition, we are also
in the process of setting up additional cancer studies with Multikine to
determine its potential as a treatment for additional types of solid
tumors."
CEL-SCI Corporation is a biopharmaceutical company whose mission is to
mobilize the immune system to combat disease.
Die Firma gibt bekannT:CEL-SCI COMPLETES EQUITY FINANCING
VIENNA, VA, March 16, 2000 -- CEL-SCI CORPORATION (AMEX: HIV, Berlin Stock
Exchange: LSR) announced today the successful completion of a sale of $7
million of the Company`s common stock to two institutional investors. The
transaction is still subject to the approval of the American Stock Exchange.
Reedland Capital Partners, a division of Financial West Group, facilitated
the transaction.
"We are very pleased by the continued confidence and support from these two
institutional investors who have previously invested in CEL-SCI," indicated
Chief Executive Officer, Geert Kersten. "Pursuant to this sale, the
Company`s cash position exceeds $15 million which we estimate is sufficient
for an additional 2 years worth of operation for the Company. We continue
to be very excited by the results we are seeing with our immunotherapy
product Multikine* which we are preparing to take into a potential phase III
clinical trial for head and neck cancer next year. In addition, we are also
in the process of setting up additional cancer studies with Multikine to
determine its potential as a treatment for additional types of solid
tumors."
CEL-SCI Corporation is a biopharmaceutical company whose mission is to
mobilize the immune system to combat disease.
Danke fuer die Info - Gomydear. CVM hat sich ja gut gehalten
waehrend der Biotechschwankungen in den USA. Ueberlege nun noch mal
einen Anlauf auf Ariad Pharma oder Immune Response zu nehmen. Interessant werden bestimmt die Phase 2 Ergebnisse von Cel-CSI sein.
Bin die Tage wieder in USA und werde mich mal umhoeren, ob es schon was neues gibt.
waehrend der Biotechschwankungen in den USA. Ueberlege nun noch mal
einen Anlauf auf Ariad Pharma oder Immune Response zu nehmen. Interessant werden bestimmt die Phase 2 Ergebnisse von Cel-CSI sein.
Bin die Tage wieder in USA und werde mich mal umhoeren, ob es schon was neues gibt.
wer weis was neues von cel-sci?
hallo leute! bin ich die einzige cel-sci aktien besitzerin?
ihr habt ja recht, laßt die finger davon!
ihr habt ja recht, laßt die finger davon!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 243 | ||
| 98 | ||
| 89 | ||
| 80 | ||
| 75 | ||
| 47 | ||
| 38 | ||
| 37 | ||
| 34 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 31 | ||
| 30 | ||
| 27 | ||
| 24 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 20 | ||
| 19 | ||
| 19 |
